MedPath

New Coating for Urinary Intermittent Catheters

Not Applicable
Recruiting
Conditions
Retention, Urinary
Registration Number
NCT06985888
Lead Sponsor
Coloplast A/S
Brief Summary

The goal is to confirm, that the newly developed coating is non-inferior to the comparator with respect to the overall discomfort of the catheterisation (assessed by participant).

Participants will attend 3 study site visits and will be catheterised by a HCP at visit 1 and 2 with one of the two catheters in randomisation order. Urine samples will be collected pre- and post catheterisation for assessments.

Detailed Description

The primary objective of the study is to confirm that the newly developed investigational coating is non-inferior to the comparator coating with respect to the overall discomfort of catheterisation.

The investigational device is a ready-to-use, sterile, hydrophilic-coated Nelaton male catheter for intermittent catheterisation and based on the standard SpeediCath® male intermittent catheter with a difference in the composition on the coating.

The study is a double-blinded, randomized, crossover study including 32 randomized healthy male volunteers. The total study duration for the individual subject will be between 4-21 days and consists of 3 site visits V0, V1 and V2, and V0 andV1 can be combined

At V1 and V2 the subjects will be catheterized in a hospital setting by a health care professional, with one of the two catheters in a randomized order. Subject will be asked to assess the overall discomfort of the catheterisation on VAS.

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
32
Inclusion Criteria
  1. Has given written informed consent
  2. Is at least 18 years old
  3. Has full legal capacity
  4. Has self-assessed intact male anatomy with no abnormalities or disease of the lower urinary tract or any surgical procedures performed in the lower urinary tract
  5. Is able (assessed by investigator) and willing to adhere to study procedures during study duration.
  6. Is able to refrain from using analgesics up to 24 hours prior to catheterisation visits
  7. Is negative for haematuria, measured by urine dipstick test of erythrocytes
Exclusion Criteria
  1. Is participating in any other clinical investigation during this investigation, which could affect the results of this investigation, as assessed by investigator.
  2. Has previously been randomized in this investigation.
  3. Has known hypersensitivity towards any of the devices used in the investigation
  4. Is currently experiencing symptoms associated with UTI, as assessed by investigator.
  5. Has known impaired sensation of the urethra

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Overall discomfort of the catheterisationimmediately after the procedure

assessed by subject using VAS

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Urology, Rigshospitalet

🇩🇰

Copenhagen, Denmark

Department of Urology, Rigshospitalet
🇩🇰Copenhagen, Denmark
Rikke Permild
Contact
+45 29619382
Per Bagi, PhD
Principal Investigator
© Copyright 2025. All Rights Reserved by MedPath